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2Abstract
On the occasion of Professor Frances H. Arnold’s recent acceptance of the 2018 Nobel Prize in Chemistry, 
we honor her numerous contributions to the fields of directed evolution and biocatalysis. Arnold pioneered 
the development of directed evolution methods for engineering enzymes as biocatalysts. Her highly 
interdisciplinary research has provided a ground not only for understanding the mechanisms of enzyme 
evolution but also for developing commercially viable enzyme biocatalysts and biocatalytic processes. In 
this Account, we highlight some of her notable contributions in the past three decades in the development 
of foundational directed evolution methods and their applications in the design and engineering of enzymes 
with desired functions for biocatalysis. Her work has created a paradigm shift in the broad catalysis field. 
Keywords: directed evolution, biocatalysis, enzyme engineering, P450s, abiological functions, carbene 
transfer reactions, nitrene transfer reactions, C–H functionalization
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3Introduction
Enzymes are the workhorses for nearly all biological processes on earth. Largely thanks to their 
exquisite specificity and selectivity, enzymes have been increasingly used as catalysts for synthesis of 
chemicals and materials. However, compared to chemical catalysts, enzymes often have limited stability, 
substrate scope and/or productivity, which significantly hinders their practical applications in industry. To 
address these key limitations in biocatalysis, in the early 1990s Frances Arnold took inspiration from nature 
and developed a simple yet powerful algorithm, called ‘directed evolution’, for evolving enzymes with 
tailored features.1 In essence, this algorithm mimics the process of natural Darwinian evolution in the test 
tube and involves subjecting a gene encoding an enzyme to random mutagenesis, followed by screening or 
selection of the resulting library for enzyme variants that show improvement of the desired function. The 
improved enzyme variant is then used as the ‘parent’ for the following round of mutagenesis and screening 
or selection, and the process is repeated iteratively until the desired goal is attained (Figure 1). Around the 
Figure 1. Workflow of a typical directed evolution experiment.
same time as this algorithm was reduced to practice by Arnold,2 another pioneer of directed enzyme 
evolution, Willem P. C. Stemmer at Maxygen, developed and applied DNA shuffling methods to engineer 
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4enzymes with tailored functions.3, 4 In the subsequent years, Arnold, Stemmer, and several other protein 
engineers around the world, including Donald Hilvert,5 Manfred Reetz,6 and Uwe Bornscheuer,7 have 
applied this algorithm in combination with state-of-the-art tools from molecular biology, genetic 
engineering, analytical chemistry, and computational biology, to evolve enzymes with improved or novel 
functions and investigate the protein structure-function relationships and evolutionary mechanisms, 
resulting in a new field of directed evolution. 
Arnold is a card-carrying engineer who was trained as a mechanical engineer as an undergraduate 
student at Princeton University and a chemical engineer as a graduate student at the University of California 
at Berkeley. Since she started her independent academic career at the Division of Chemistry and Chemical 
Engineering at Caltech in the mid-1980s, she has been exploring enzymes for biocatalytic applications and 
fundamental research. In this Account, we will first highlight some of her pioneering contributions in the 
development and application of directed evolution tools for enzyme engineering in the 1990s, which laid 
the foundation for the directed evolution field. We will then survey her work on the synthetically versatile 
P450 monooxygenases as an example to illustrate her group’s key contributions in engineering enzymes 
with improved catalytic efficiency or new substrate specificity, and understanding the evolutionary 
mechanisms and protein structure-function relationships. Finally, we will highlight her recent contributions 
in evolving enzymes with abiological function, which has contributed to expand the boundaries of 
traditional biocatalysis. With the Arnold group continuing to be innovative and highly productive, this 
Account only serves as a mid-point review of Frances Arnold’s long and illustrious career in biocatalysis. 
I. Early Days in Directed Enzyme Evolution 
Thanks to the advances in recombinant DNA technologies and protein crystallography, the 
mainstream school of thought in enzyme engineering in the 1980s was to use rational design approaches 
based on structural analysis and site-directed mutagenesis. Frances Arnold was among the first chemical 
engineers who adopted rational design approaches for enzyme engineering. For example, the Arnold group 
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5introduced rationally designed new metal binding sites into enzymes to improve their stability.8, 9 However, 
Arnold quickly recognized the limitations of rational design which was mainly due to our limited 
understanding of enzyme structure, function, and dynamics as well as catalytic mechanisms. Therefore, in 
the late 1980s, inspired by the early studies of John Maynard Smith10 and Manfred Eigen11, Arnold decided 
to explore molecular evolutionary strategies for engineering enzymes with improved stability and activity.  
In her seminal work2, Arnold used iterative rounds of random mutagenesis coupled with screening 
to improve the activity of subtilisin E in 60% dimethylformamide by 256-fold. This work not only described 
the directed evolution algorithm and all the key steps in a directed evolution experiment, but also 
demonstrated that beneficial mutations could be accumulated gradually to yield drastic changes in protein 
functions and that many of these beneficial mutations were unexpected. This work inspired many other 
research groups to use directed evolution as an enzyme engineering strategy. However, one limitation with 
this random mutagenesis based directed evolution strategy was that deleterious mutations may be 
accumulated too, which resulted in less optimal enzymes. To address this limitation, Arnold group 
developed a staggered extension process (StEP) in vitro recombination method12, which not only 
accumulates the beneficial mutations but also removes the deleterious mutations by randomly shuffling the 
improved genes during each round of directed evolution. In addition to StEP recombination, which was 
inspired by Stemmer’s ‘DNA shuffling’ idea3, 4, Arnold’s group developed a range of directed evolution 
tools and strategies, such as the optimized DNA shuffling method13, in vitro random priming recombination 
method14, digital imaging based on high throughput screening methods for oxygenases15, 16,  and SCHEMA 
structure-guided recombination, which enables extension to more distantly-related genes17.
Apart from developing new directed evolution tools and strategies, the Arnold group also applied 
them to solve some practical challenges in biocatalysis. For example, a para-nitrobenzyl esterase was 
engineered with improved stability18, as well as new substrate specificity and improved activity in aqueous-
organic solvents19. Para-nitrobenzyl alcohol is used to protect carboxylic acid functionalities during the 
synthesis of cephalosporin-derived antibiotics, and the engineered para-nitrobenzyl esterase can be used to 
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6remove the para-nitrobenzyl alcohol protecting group during the synthesis of loracarbef, a fourth-
generation cephalosporin-derived antibiotic. In addition, the Arnold group engineered a subtilisin E variant 
with drastically improved stability, which showed nearly identical thermal stability as a naturally occurring 
thermostable subtilisin, thermitase, yet was highly active at a much broader spectrum of temperatures than 
the thermitase20. 
II. P450 BM3: a model enzyme for directed evolution
Starting from the late 1990s, protein engineering efforts in the Arnold group began to focus on 
P450 monooxygenases.21, 22 Cytochrome P450 monooxygenases make up a large class of heme-dependent 
enzymes23 which have evolved across all kingdoms of life to carry out a myriad of oxidation reactions, 
while sharing a common three-dimensional fold.24-27 This enzyme superfamily provides an impressive 
example of how nature can generate a broad range of oxidation catalysts from a common protein scaffold. 
Whereas all these enzymes share a cysteine-ligated heme cofactor that is responsible for their activity, the 
widely diverse substrate specificity of P450s is dictated by their protein sequences, which have diverged as 
much as 90% over the course of millions of years of natural evolution.24-26  
Inspired by the functional pliability of natural P450s, the Arnold group identified cytochrome P450 
from Bacillus megaterium (P450 BM3) a particularly attractive target for directed evolution experiments. 
At that time, P450 BM3 was one of very few known P450s in which the heme domain is fused to a diflavin 
(FMN/FAD) reductase domain in a single polypeptide chain.28-30 This structural arrangement makes P450 
BM3 catalytically ‘self-sufficient’ and able to support the oxidation of a substrate with the only requirement 
of air oxygen and a source of reducing equivalents in the form of the nicotinamide adenine dinucleotide 
phosphate (NADPH) cofactor. In addition, P450 BM3 is soluble, it can be readily expressed in Escherichia 
coli, an excellent host for laboratory evolution experiments, and it is one of the most active hydroxylases 
known, supporting the hydroxylation of its preferred substrates, long-chain (C12-C20) fatty acids, with 
rates exceeding 1,000 turnovers per minute.29  
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7While in those years protein engineering efforts with BM3 or other P450s were being pursued using 
structure-based mutagenesis,31-36 the Arnold group was interested in applying directed evolution to create 
P450-based catalysts with altered substrate specificity and/or increased stability. One of the earliest goals 
in the group was to evolve P450 BM3 to accept linear alkanes as substrates for hydroxylation, including 
the short-chain gaseous alkenes (propane, ethane, methane) found in natural gas. Such biocatalysts were 
envisioned to provide a potential approach for the biotransformation of natural gas into liquid alcohols as 
more convenient and easily transportable fuels. In nature, gaseous alkanes are hydroxylated by multi-
component non-heme iron monooxygenase enzymes such as methane monooxygenases. Whereas the 
structural complexity of these enzymes complicates their use or engineering for biotechnological 
applications, they are also structurally and mechanistically distinct from P450s, begging the question of 
whether a P450 could be evolved to mimic their function. A challenge inherent to this goal was the fact the 
P450 BM3 had no detectable activity on propane or smaller alkanes, providing no obvious path for the 
improvement of such activity. The Arnold group thus decided to initially improve its hydroxylation activity 
on octane, which is a poor but viable substrate for this P450,22, 37 with the underlying idea that BM3 variants 
with enhanced octane activity would eventually acquire the ability to accept and hydroxylate shorter 
alkanes. After five generations of random mutagenesis targeted to the heme domain, followed by 
recombination of beneficial mutations, the group was able to identify a P450 BM3 variant (139-3) with 
significantly improved octane activity (30 → 1,000 total turnovers (TTN)) as a result of 11 amino acid 
substitutions accumulated over the course of this process.22 Importantly, such enhancement in octane 
activity was accompanied by the acquisition of activity on the smaller alkane substrate propane (0 → 500 
TTN).38 Further rounds of mutagenesis and screening, using first an octane surrogate substrate and then a 
propane surrogate substrate, led to P450 BM3 variants with progressively increased activity toward the 
conversion of propane to 2-propanol and even modest activity on ethane (up to 250 TTN with variant 
35E11).38, 39 Out of the 17 mutations accumulated in 35E11, only two were found to be located in the active 
site, illustrating the power of directed evolution in identifying beneficial mutations far from the active site. 
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8Integral part of this evolutionary process was the development of high-throughput assays for enabling the 
rapid screening of P450 libraries for activity on chromogenic substrates as surrogates for octane (p-
nitrophenyl octyl ether and hexyl methyl ether) and propane (dimethyl ether).37, 38
Despite this progress, the catalytic efficiency of 35E11 as an alkane hydroxylase was significantly 
inferior compared to that of wild-type P450 BM3 on its preferred substrates. The function of this multi-
domain P450 relies on finely regulated conformational changes and electron transfer mechanisms, which 
ensure efficient coupling of fatty acid hydroxylation with NADPH oxidation.29 These mechanisms are 
disrupted in the presence of non-native substrates and/or as a result of mutations, resulting in an 
‘uncoupling’ process and production of reactive oxygen species (ROS) which inactivates the enzyme. To 
obtain a more efficient biocatalyst for propane hydroxylation, variant 35E11 was further evolved using a 
‘domain engineering strategy’, in which beneficial mutations within the heme-, FMN-, and FAD-domain 
of this P450 were first identified via random and site-saturation mutagenesis and then combined in a final 
step.40  This process generated a proficient propane monooxygenase, named P450PMO, possessing high 
catalytic efficiency and coupling efficiency for this reaction (Figure 2), i.e. catalytic properties comparable 
to those exhibited by wild-type P450BM3 with its preferred substrates.40, 41 The laboratory-evolved P450PMO 
could then be applied for the efficient conversion of propane to 2-propanol in metabolically engineered E. 
coli cells.42 
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9Figure 2. Directed evolution of a cytochrome P450 propane monooxygenase. The long-chain fatty acid 
hydroxylase P450 BM3 from Bacillus megaterium was converted into a highly efficient propane 
monooxygenase (P450PMO) over 13 rounds of directed evolution.22, 38, 40 The evolved enzyme accumulated 
3 beneficial mutations in the reductase domain and 20 in the heme domain (yellow, sphere models), many 
of which are distant from the heme cofactor (red, sphere model). Refinement of catalytic efficiency for 
propane oxidation, an activity not exhibited by wild-type P450 BM3, also involved a profound reshaping 
and partitioning of the substrate access pathway (inserts).41
 
Lessons from directed evolution experiments 
The conversion of P450 BM3 into an efficient propane monooxygenase not only demonstrated the 
remarkable plasticity of P450s toward adopting new functions but also the effectiveness of directed 
evolution in progressively adapting an enzyme to execute a new function. This ‘substrate walk’ strategy 
has proven effective in the laboratory evolution of a variety of other enzymes and proteins.43-48 In addition 
to altered substrate specificity, the Arnold group demonstrated over the years how a variety of other 
properties of P450s, including the ability to operate as peroxygenases, i.e., catalyze hydroxylation reactions 
driven by hydrogen peroxide,49 and their stability against thermal50 and chemical denaturation51 could be 
improved through directed evolution. These studies, along with a growing number of examples from other 
groups, notably in the case of enantioselective transformations,52, 53 contributed to formulate the now 
broadly accepted notion that the fitness of a protein with respect to a given functional or structural property 
can be gradually enhanced in the laboratory, often through a series of small mutational steps,54 as long as 
the desired property remains feasible and properly chosen screening/selection tools are applied. 
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10
Figure 3. Catalytic and stability properties (a) and substrate profile (b) of selected variants along the 
P450PMO lineage.41 Total turnover numbers (TTN), coupling efficiency (mol oxidized product/mol oxidized 
NADPH), and kinetic properties (KM, kcat) refer to propane oxidation. Thermal stability is shown as T50 
(half-maximal inactivation temperature after 10-min incubation). Substrate profile is reported as relative 
activity on C1–C10 alkane series. Adapted with permission from ref. 41. Copyright 2008, Elsevier.
Important lessons on how proteins can evolve were also derived from a detailed characterization 
of the evolutionary intermediates along the lineage of P450PMO (Figure 3A).41 These studies revealed that 
the adaptive walk from the long-chain fatty acid hydroxylase P450BM3 to the propane monooxygenase 
P450PMO proceeded through a series of ‘promiscuous’ variants (e.g. 139-3, 35E11) that are characterized 
by a broad substrate profile, as determined based on their activity profile across the series of C1-C10 alkanes 
and other substrates.41 However, further optimization of propane activity was accompanied by ‘re-
specialization’ of the P450 for the new function (Figure 3B), resulting in a variant (P450PMO) that features 
a very narrow substrate profile centered around propane and has no residual activity on fatty acids, i.e. no 
remnants of the enzyme native function.41 On the one hand, these experiments showed that, starting from a 
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11
specialized enzyme, the acquisition of a new substrate activity can proceed via a ‘generalist’ enzyme, with 
modest activity on multiple substrates in addition to the native one(s). On the other hand, given that no 
negative selection was applied throughout the directed evolution of P450PMO, these studies also showed that 
positive selection alone (i.e. propane activity) was sufficient for evolving a ‘specialist’ enzyme from another 
specialized one. Prior to this work, it was generally assumed that a combination of positive and negative 
selection pressure was necessary to reinforce the desired phenotype in an enzyme/protein while removing 
undesirable native (or non-native) activities, as supported by a number of protein engineering 
experiments.55-57
The P450PMO ‘story’ also illustrated the importance of addressing the activity/stability trade-off 
often observed in directed evolution experiments. Indeed, at a point during the evolution of P450PMO – 
specifically at the level of 35E11 (Figure 3A), thermostabilization of the protein (via function-neutral 
mutations) was necessary to enable the accumulation of additional beneficial mutations to enhance propane 
activity.41 This finding reiterated the important relationship between protein stability and evolvability, a 
notion nicely outlined in a previous study of the Arnold group.58 Via a comparative study with a marginally 
stable vs. a highly stable variant of BM3, they indeed demonstrated how the thermostable P450 showed a 
significantly higher propensity to acquire activity on new substrates upon random mutations when 
compared to the less stable enzyme. This study thus illustrated the key role of stability-based epistasis in 
adaptive evolution,59 an important implication of which is that, in the realm of natural proteins, function-
neutral yet stabilizing mutations may accumulate by genetic drift to permit the evolution of new functions.60  
In another study involving P450 BM3 as a model enzyme, Arnold and coworkers further demonstrated that 
promiscuous enzymatic activities (e.g. activity on a new substrate) can arise via a neutral path, i.e., through 
mutations that are neutral to the property under selective pressure,61 and these can provide the starting points 
for the evolution of new functional proteins.
The Arnold group’s interest toward investigating the impact of mutational events on emergence of 
new functions has also extended to recombination, a key mechanism occurring in the context of natural 
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12
protein evolution. In particular, the group introduced a new strategy for directed evolution via 
recombination of homologous enzymes, called SCHEMA, which relies on the structure-based identification 
of crossover points for minimizing structural disruption in the resulting chimeras. Using the -lactamase 
scaffold as a testbed, a large set of chimeric proteins was generated by SCHEMA-guided recombination of 
the homologous -lactamase enzymes TEM-1 and PSE-2 and analyzed for retention of function (Figure 
4A). This study showed that recombination is conservative (much more so than random mutagenesis) and 
results in a higher frequency of folded and functional variants despite of the introduction of multiple amino 
acid mutations compared to the parent enzymes (Figure 4B).62 To address the question of whether these 
mutational changes are associated with the acquisition of new functional traits, similar recombination 
experiments were conducted using three homologs of P450 BM3 sharing ~65% sequence identity.63 This 
process generated a new family of ~6,000 chimeric P450s carrying an average of 70 mutations from the 
closet parent, approximately half of which folded properly and a third of which display enzymatic activity. 
Characterization of these chimeric P450s revealed that functional members of these libraries acquired 
significant functional diversity, including the ability to accept substrates not accepted by the parent 
enzymes.64  In addition, a fraction of the chimeric P450s were found to exhibit higher stability compared to 
the parent proteins (Figure 4C) and, based on structure-stability correlations, highly thermostable variants 
could be generated through the targeted recombination of stabilizing fragments.65 The same overall 
approach later proved valuable toward generating thermostabilized and functional variants of fungal 
cellobiohydrolases, which find utility in the degradation of cellulose into fermentable sugars for biofuel 
applications.66 Overall, these studies contributed to demonstrate the value of structure-based recombination 
as a strategy to navigate the functional space in enzymes and provide valuable starting points for further 
functional evolution.  
Page 12 of 33
ACS Paragon Plus Environment
ACS Catalysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13
Figure 4. Directed evolution of enzymes using structure-based recombination. (a) Generation of 
chimeric enzymes via SCHEMA-guided recombination of fragments derived from homologous parent 
sequences and chosen to minimize structural disruption.17 (b) SCHEMA-guided recombination of -
lactamase PSE-2 and TEM-1 produces a higher fraction of functional chimeras compared to random 
mutagenesis.62 (c) Chimeric P450s obtained via SCHEMA-guided recombination of P450 BM3 
(CYP102A1) with its homologous enzymes CYP102A2 and CYP102A3 can exhibit higher stability against 
thermal denaturation compared to any of the parent P450s.65 Adapted with permission from ref. 62. 
Copyright 2005, National Academy of Sciences. 
Laboratory-evolved P450s for biocatalytic oxidations  
Oxidation catalysts are valuable tools for a variety of synthetic applications,67 and the synthetic 
potential of (engineered) cytochrome P450s in this regard has not been overlooked by Frances Arnold, 
along with a number of other groups.68-71 In particular, Arnold and coworkers demonstrated how substrate 
promiscuous P450 BM3 variants isolated during the evolution of alkane oxidases could be useful for the 
selective hydroxylation of C6-C10 alkanes at the subterminal (-1) position (up to 86% regioselectivity and 
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83% ee)38, the epoxidation of terminal C5-C8 alkenes (up to 94% regioselectivity and 83% ee; Scheme 
1A)72, and the -hydroxylation of 2-aryl-acetic acid esters to give valuable mandelic acid derivatives (up 
to 99% regioselectivity and 94% ee; Scheme 1B)73. In another contribution, it was shown that P450-
catalyzed hydroxylation could be combined with chemical fluorination to enable the rapid and site-selective 
installation of one or more fluorine substituents in a variety of target small-molecule drugs and building 
blocks.74 As the C–H sites targeted by engineered bacterial P450s often overlap with those oxidized by 
human liver P450s, this strategy is valuable toward improving the metabolic stability of drugs or other 
bioactive molecules.74, 75   
Since hepatic P450s account for the majority of Phase I metabolic transformations of drugs in vivo, 
an important application of cytochrome P450s (human and non-human) lies in the production of the 
authentic human metabolites of drugs and drug candidates,76-79 as characterization of the pharmacological 
activity and toxicity of these compounds represents a critical step toward their approval for use as 
pharmaceuticals. Along with others,80, 81 the Arnold group showed that laboratory-evolved variants of P450 
BM3, including substrate-promiscuous variants from the aforementioned P450PMO lineage and 
recombination libraries, can prove useful to generate human metabolites of marketed drugs.82, 83 In 
collaborative effort with Eli Lilly, Arnold and coworkers showed the successful application of a small 
collection of these engineered P450BM3 variants (~120) for producing nearly all of the human metabolites 
(12/13) of the drugs verapamil and astemizole.83 They also reported the directed evolution of a P450BM3 
variant for the oxidation of acidic drugs such as naproxen, which are typically metabolized by human 
CYP2C9.84 
In another important synthetic application, P450 BM3 variants were engineered by the Arnold 
group to enable the regioselective deprotection of single methyl groups from permethylated 
monosaccharides.85 The deprotected monosaccharides could be then converted in a chemoenzymatic 
process to deoxy- and fluorinated monosaccharides and disaccharides, thus providing a new approach to 
access valuable building blocks for the synthesis of polysaccharides and other sugar-functionalized 
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molecules. While P450-mediated chemoenzymatic synthesis has recently emerged as an attractive strategy 
for the late-stage functionalization of complex bioactive molecules,75, 86, 87 a collaboration between the 
Arnold and Stoltz groups recently demonstrated the utility of engineered P450s for the total synthesis of 
the natural product nigelladine A.88 In this case, a key allylic oxidation step, which had proven inefficient 
using chemical methods, could be realized using an engineered P450 BM3 variant, enabling further 
elaboration of the synthetic intermediate to the desired natural product. 
O
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Me
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% ee
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D
Scheme 1. Laboratory-evolved P450 BM3 variants for synthetic applications: (a) selective epoxidation of 
terminal alkenes;72 (b) stereoselective synthesis of mandelic acid derivatives;73 (c) generation of human 
drug metabolites (sites hydroxylated by the engineered P450 BM3 variants are indicated by arrows);83 and 
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(d) regioselective demethylation of permethylated monosaccharides.85 TON = turnover number; ee = 
enantiomeric excess; select. = selectivity.
III. Evolving enzymes for new-to-nature biotransformations
Starting in 2010, protein engineering efforts in the Arnold group began to focus on the evolution 
of cytochrome P450s for abiological functions such as carbene and nitrene transfer 
reactions. These are synthetically valuable transformations not known 
in naturally-occurring enzymes. The contributions of the Arnold group 
and others89-100 in this area have greatly expanded the repertoire of enzymes 
as biocatalysts for synthetic applications. 
The preparation of cyclopropanes by carbene transfer to olefins, though well known in transition 
metal catalysis,101, 102 is novel to the biological world. In 2013, the Arnold group showed that heme proteins 
such as engineered cytochrome P450 BM3 enzymes could function as cyclopropanation biocatalysts, 
promoting the cyclopropanation of styrenyl olefins in water.103 By mutating the proximal axial ligand from 
cysteine to serine, variants of P450BM3 (termed P411BM3 because of the signature ferrous CO Soret peak at 
411 nm rather than 450 nm for cysteine-ligated P450) also function efficiently in whole-cell E. coli and 
catalyze carbene transfer styrene cyclopropanation in vivo with up to 67,800 turnovers.104
Enzymes are sustainable catalysts for the preparation of pharmaceuticals and other high-value 
compounds,105, 106 and new-to-nature enzymatic activities can significantly expand the biocatalytic 
repertoire available for this purpose.107 Taking advantage of the versatility of engineered cytochromes 
P45098, 100, 108, 109 as cyclopropanation enzymes, the Arnold group showed their potential for producing 
industrially important pharmaceutical building blocks such as the cyclopropane core of the antidepressant 
levomilnacipran, which was prepared on a preparative scale using P450BM3-Hstar, an evolved His-ligated 
cytochrome P450BM3 variant (Scheme 2A).110 Stereocomplementary biocatalysts are key assets for the 
synthesis of drugs and complex molecules.94, 111-119 Upon exploring a collection of heme enzymes, the 
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Arnold group was able to identify a set of biocatalysts useful for producing the four possible stereoisomers 
of a cyclopropanation reaction with ethyl diazoacetate and an unactivated alkene (Scheme 2B).120 Notably, 
no iron-based catalyst was previously known for this transformation and heme alone only catalyzed this 
reaction with < 1 turnover.
Ph N2
O
OEt
+
CO2Et
E. coli harboring
P450BM3-Hstar
86% yield
98:2 dr, 92% ee
NEt2
O Ph NEt2
O
aerobic
preparative scale
Ph NEt2
O
NH4Cl
levomilnacipran
nHex N2
O
OEt
+
nHex CO2Et
E. coli harboring
heme protein
nHex CO2EtnHex CO2Et
nHex CO2Et
P411BM3-UA V87C P411BM3-UA V87F
A. pernix protoglobin
W59A Y60G F145W
R. marinus nitric oxide
dioxygenase Q52V
270 TTN
95:5 dr, 97% ee
490 TTN
89:11 dr, 99% ee
310 TTN
4:96 dr, 96% ee
100 TTN
<1:99 dr, >99% ee
A
B
Scheme 2. Engineered heme protein-catalyzed new-to-nature transformations: (a) synthesis of the 
cyclopropane core of antidepressant levomilnacipran;110 (b) enzymatic stereodivergent  cyclopropanation 
of octene catalyzed by a suite of engineered cytochrome P411 proteins and globins.120
Highly strained rings
Bicyclobutanes are puckered carbocycles that are difficult to assemble owning to their high ring 
strain. Once synthesized, however, they manifest interesting properties that make them uniquely suited for 
a variety of applications, such as strain-release chemistry121 and stimulus-responsive materials.122 In a recent 
study, the Arnold group described the directed evolution of a P411 variant, called P411BM3-E10-FA, capable 
of accepting phenylacetylene and ethyl diazoacetate as substrates to make bicyclobutane product as a single 
stereoisomer (Scheme 3).123 Key to this success is the enzyme’s ability to stabilize the putative reactive 
cyclopropene intermediate and exert precise stereocontrol over two carbene transfer events. P411BM3 
variants that yield cyclopropenes as the final products were also identified, such that each enantiomer of a 
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cyclopropene can be made enzymatically with thousands of turnovers and high enantioselectivity (Scheme 
3). 
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N N
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EtO2C H
H
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n=2n=2 n=2
Scheme 3. Cytochrome P411BM3-catalyzed bicyclobutanation and cyclopropenation.123
New chemical bonds
Carbon–silicon and carbon–boron bonds are absent in biology but commonly found in man-made 
molecules and materials in our modern world. By engineering cytochrome c protein from the 
thermohalophilic bacterium Rhodothermus marinus (Rma cyt c), the Arnold group described carbene 
insertion into Si–H and B–H bonds as a means to coax bacteria to forge carbon–silicon and carbon–boron 
bonds in living systems for the first time.124, 125 With only three mutations, directed evolution turned wild-
type Rma cyt c into a silylation enzyme that exhibits up to 8,200 turnovers (Scheme 4A), capable of making 
20 different organosilicon products with 95-99% ee.122 The mechanism of biological carbon–silicon bond 
formation was elucidated by the Arnold and Houk groups by capturing the catalytic iron-carbene 
intermediate in the active site of Rma cyt c crystallographically (Scheme 4A) and by probing 
experimentally and computationally how the iron-carbene electronic state and protein conformational 
dynamics affect the reaction.126 These efforts are complemented by the mechanistic work of other groups, 
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further our understanding of how iron porphyrins and heme proteins catalyze carbene transfer to olefins, 
N–H, and C–H bonds.127-133 
Genetically programmable chiral organoborane synthesis was also realized by the laboratory 
evolution of Rma cyt c.123 This platform successfully yields structurally distinct organoboranes through 
divergent directed evolution (Scheme 4B), providing bacterial borylation catalysts that are suitable for 
gram-scale biosynthesis, and offering up to 15,300 turnovers and excellent selectivity (99:1 e.r., 100% 
chemoselectivity). Moreover, these enzymes are readily tunable to accommodate the synthesis of lactone-
based organoboranes134 and a broad range of chiral α-trifluoromethylated organoboranes (Scheme 4C).135 
The latter demonstration is particularly appealing as it represents a means to introduce fluorine-containing 
motifs to small molecules,95 orthogonal to existing strategies for organofluorine biosynthesis using 
engineered fluorinase enzymes or precursor-directed biosynthesis of fluorine-containing polyketides, 
peptides, and alkaloids.136, 137 
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Scheme 4. Engineered R. marinus cytochrome c-catalyzed carbon–silicon124 and carbon–boron bond 
formation.125, 135
C–H functionalization
Evolving heme proteins to functionalize C–H bonds in new ways is of interest to the Arnold group 
and others in the biocatalytic community.138 While native P450 enzymes are well versed in oxidizing even 
unactivated C–H bonds through a reactive, high-valent iron-oxene intermediate (Compound I),139 other than 
oxygen atoms, examples of heme proteins inserting other groups or functionalities into C–H bonds are 
sporadic in the natural and unnatural worlds. Inspired by a 1985 report describing a C–H amination reaction 
catalyzed by rabbit liver cytochrome P450,140 the Arnold and Fasan group independently discovered that 
engineered P411 (P411BM3-T268A and P411BM3-CIS)141 and P450BM3 variants,89 as well as other 
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hemoproteins142, are able to catalyze and intramolecular nitrene insertion into benzylic C–H bonds on aryl 
sulfonyl azides. By further evolving these P411 variants through active site site-saturation mutagenesis and 
recombination of beneficial mutations, the regioselectivity of the cyclization process could be altered to 
yield either five-membered (benzylic C–H insertion) or six-membered ring (homobenzylic C–H insertion) 
products, representing a powerful example of how directed evolution can tune an enzyme active site to 
favor functionalization of higher-energy C–H bonds (Scheme 5A).143 
Recently, this concept was further expanded and showcased in the divergent synthesis of β-, γ-, and 
δ-lactams by P411BM3-catalyzed intramolecular C–H amidation.144 Using acyl-protected hydroxamates as 
carbonyl nitrene precursors90, 145, a collection of P411BM3-derived lactam synthases with complementary 
cyclization modes was obtained (Scheme 5B). Remarkably, these biocatalysts can override intrinsic 
substrate bias from sterics, electronic preference, and ring strain to deliver lactams of different ring sizes 
with excellent selectivities and up to a million total turnovers.
Intermolecular C–H amination is a significantly challenging transformation and few catalytic 
systems are known to be both efficient and selective across diverse substrates. To overcome this, many 
heme proteins were tested in the Arnold group for intermolecular nitrene C–H insertion activity: none was 
found to be active until they tested a cytochrome P411BM3 variant, called P4, engineered for the nitrene 
transfer to sulfides and allylic sulfides.146, 147 The promiscuous activity observed may arise from transition 
state similarities between sulfimidation and nitrene C–H insertion. Introducing four mutations to P4 (A82L, 
A78V, F263L, and E267D) led to P411CHA, a highly enantioselective benzylic C–H amination biocatalyst 
capable of catalyzing a reaction which the iron cofactor alone cannot perform (Scheme 5C). Interestingly, 
P4 A82L also exhibits intermolecular C–H alkylation activity, unlocking a whole new world of 
opportunities for developing enzymatic C–H functionalization methods by carbene transfer.148 After 13 
rounds of mutagenesis and screening and removal of the enzyme FAD domain, P411-CHF was created 
from P4 A82L, which demonstrates 140-fold turnover increase relative to the parent protein in carbene 
transfer C–H insertion reaction of p-methoxybenzyl methyl ether. P411-CHF is broad in scope: it 
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functionalizes benzylic, allylic, and α-amino C–H bonds with up to 3750 turnovers and >99:1 er, and is 
applicable to streamlining the synthesis of natural products (Scheme 5D). Because this biocatalyst is fully 
genetically encoded, produced in E. coli, and functions at room temperature, it offers a desirable alternative 
to noble-metal catalysts for intermolecular C–H functionalization chemistry.  
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Scheme 5. C–H functionalization enabled by enzymatic nitrene and carbene transfer C–H insertion: (a) 
regioselective cyclization via intramolecular nitrene insertion into benzylic C–H bonds;143 (b) divergent 
synthesis of β-, γ-, and δ-lactams by P411BM3-catalyzed intramolecular C–H amidation;144 (c) P411BM3-
catalyzed intermolecular C–H amination;147 (d) P411BM3-catalyzed intermolecular C–H alkylation.148
Summary
Frances Arnold pioneered the development of directed evolution for enzyme engineering. Her career has 
not only had a profound impact in the field of enzyme engineering and biocatalysis but also deeply 
influenced the lives of many of her students and postdocs, including the three of us. This account articles 
revisit some of her inspiring accomplishments over the past three decades and we are sure that more 
groundbreaking contributions will be forthcoming in the coming years, as a direct result of her fearless and 
tireless pursuit of excellence in research.
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